Exhibit 4.4

Collaboration Agreement

COLLABORATION AGREEMENT dated this 18th day of December, 2002 by and between CRUCELL N.V. and CRUCELL HOLLAND B.V., both Netherlands corporations having offices
at Archimedesweg 4, 2333 CN, Leiden, The Netherlands (jointly and severally "Crucell") and DSM BIOLOGICS HOLDING, INC. and DSM BIOLOGICS COMPANY, INC., Quebec corporations having offices
at 6000 Royalmount Avenue, Montreal, Canada and DSM BIOLOGICS COMPANY, B.V., a Netherlands corporation having offices at Zuiderweg 72/2, Groningen, The Netherlands (jointly and severally "DSM").

R E C I T A L S:

A.    Crucell
is the owner of certain patents, know-how, expertise and other proprietary technology relating to the establishment and maintenance of a human cell
line (as more specifically defined herein, "PER.C6 Cells") which Crucell is developing as an expression platform for the development and manufacture of biopharmaceutical products.

B.    DSM
is engaged, among other things, in the contract development and manufacture of biopharmaceutical products. DSM desires to increase and improve its manufacturing
technology and capacity in order to provide product development and contract manufacturing services to the pharmaceutical and biopharmaceutical industries.

C.    In
order to further such development activities and increase their commercial applicability, Crucell and DSM desire to collaborate on the commercialization of PER.C6 Cell
technology and on the
development of large scale manufacturing technology utilizing PER.C6 Cells, in each case as an expression platform to produce research and commercial quantities of pharmaceutical products. To that
end, the parties have agreed to perform certain research and development activities, to grant certain licenses and to facilitate related technology transfers, all in accordance with the terms and
conditions hereinafter set forth.

NOW,
THEREFORE, in consideration of the foregoing and of the mutual terms and conditions hereinafter set forth, the parties hereto hereby agree as follows:

1.Definitions.In addition to terms defined hereinafter in this Agreement, as used herein the following terms
shall have the respective meanings set forth below:



1

---



2

---



3

---



2.Development Program.



4

---



5

---



3.License Grants; Technology Transfer.



6

---



7

---



4.Commercialization.



8

---



5.Consideration for Crucell Technology; Collaboration Revenues.



9

---



10

---



6.Intellectual Property.



11

---



12

---







7.Representations, Warranties and Indemnification.



13

---



8.Confidentiality.



14

---



9.Term and Termination



15

---



If Termination Occurs

Residual ShareBefore Time for Section 5.1.2 Payment

% of DSM ShareAfter Time for Section 5.1.2 Payment and provided that such payment has been made by DSM But Before Time for Section 5.1.3 Payment

% of DSM ShareAfter Time for Section 5.1.3 Payment and provided that such payment has been made by DSM But Before Time for Section 5.1.4 Payment

% of DSM ShareAfter Time for Section 5.1.4 Payment and provided that such payment has been made by DSM But Before Time for Section 5.1.5 Payment

% of DSM ShareAfter Time for Section 5.1.5 Payment and provided that such payment has been made by DSM

% of DSM Share




16

---



10.Miscellaneous.



17

---



To Crucell:

Crucell Holland B.V.
Archimedesweg 4,
2333 CN, Leiden
The Netherlands
Attn: Chief Business Officer
Facsimile No.: 31 71 524 8720With a copy to:
Office of Chief Counsel
Facsimile No.: 31 71 524 8720To DSM:

DSM Biologics
PO Box 43
6130 AA Sittard
Attn: Chief Executive Officer
Facsimile No.: 31 46 477 3179
With a copy to:
Legal Counsel
Facsimile No.: 31 46 477 3179




18

---



Notwithstanding
the foregoing, the parties shall agree upon a press release to announce the execution of this Agreement and the parties agree to schedule, coordinate and agree upon the
terms of a joint press conference with respect to this Agreement and the collaboration contemplated hereby; thereafter, Crucell and DSM may each disclose to third parties the information contained in
such press release and Q&A without the need for further approval by the other



19

---



IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered in duplicate originals as of the date first above written.

| |  | CRUCELL N.V.               
| |  | ---------------------------
| |  | By:                        
| |  |                            
| |  | CRUCELL HOLLAND BV         
| |  | By:                        
| |  |                            
| |  | DSM BIOLOGICS HOLDING, INC.
| |  | By:                        
| |  |                            
| |  | By:                        
| |  |                            
| |  | DSM BIOLOGICS COMPANY, INC.
| |  | By:                        
| |  |                            
| |  | By:                        
| |  |                            
| |  | DSM BIOLOGICS COMPANY, B.V.
| |  | By:                        
| |  |                            
| |  | By:                        
| |  |                            

20

---

QuickLinks